Imaging Technology

AUGUST 29, 2023

Alan Taylor , stated, “Large-scale manufacture of therapeutic Cu-67 from highly efficient, environmentally preferable electron accelerators is critical to overcome the widespread supply issues in the radiopharmaceutical industry, due to a heavy reliance on a small number of antiquated nuclear reactors.

Pharmaceutical 73

Pharmaceutical Radiopharmaceuticals Clinic Medical 73

AuntMinnie

MARCH 25, 2024

Coronary artery disease (CAD) is the leading cause of mortality in the U.S. In a cohort of 1,282 patients who underwent invasive coronary angiography for suspected disease, noninvasive PET MPI performed within six months identified large perfusion defects (>10% of the left ventricular myocardium) in 82% of the patients.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JANUARY 30, 2024

The timing of the new codes dovetails with advances in neuroimaging, such as in the assessment of white-matter diseases. A widely used class of radiopharmaceuticals in the study of the neuroinflammatory response targets the translocator protein (TSPO), according to the researchers.

MRI 101

MRI Radiopharmaceuticals Disease Imaging 101

Imaging Technology

JUNE 20, 2024

Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system, but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities.

Healthcare 78

Healthcare Healthcare Nuclear Medicine Computed Tomography 78

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic 72

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 72

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 89

Diagnostic Radiopharmaceuticals Imaging Radiation 89

Imaging Technology

JULY 28, 2023

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Executive Officer of the Company. “We

Clinic 81

Clinic Diagnostic Radiopharmaceuticals Radiation 81

Imaging Technology

SEPTEMBER 27, 2023

PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging Presenter: Phillip H. in Newly Diagnosed Prostate Cancer Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3

Diagnostic 90

Diagnostic Radiation Oncology Radiation Clinic 90

Imaging Technology

JULY 20, 2023

He focuses on treating pediatric patients as well as adults diagnosed with brain, spine and other central nervous system tumors. Keole is a radiation oncologist at the Mayo Clinic in Scottsdale, Arizona and also sees patients at Phoenix Children’s Hospital.

Radiation Oncology 79

Radiation Oncology Radiation Government Community Practice 79

Imaging Technology

MAY 23, 2023

More than one million people receive radiation therapy each year to treat cancer and other diseases, yet ongoing cuts, prior authorization and rising costs threaten to undermine equitable access to this life-saving treatment. in the past three decades.

Radiation Oncology 67

Radiation Oncology Radiation Clinic Medicare 67